{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:40:13Z","timestamp":1792518013643,"version":"4.5.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008467","name":"Canadian Association of Radiation Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008467","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022795","name":"Hamilton Health Sciences Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.canlet.2026.218535","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T15:11:00Z","timestamp":1777043460000},"page":"218535","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Canagliflozin is a novel androgen receptor pathway inhibitor for castrate-sensitive and castrate-resistant prostate cancer"],"prefix":"10.1016","volume":"652","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1750-0605","authenticated-orcid":false,"given":"Amr","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiorella","family":"Di Pastena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga-Demetra","family":"Biziotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3467-396X","authenticated-orcid":false,"given":"Simon","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia E.","family":"Tsakiridis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7838-155X","authenticated-orcid":false,"given":"Daniel","family":"Del Rosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1223-0754","authenticated-orcid":false,"given":"James C.","family":"Fredenburgh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey I.","family":"Weitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9286-1972","authenticated-orcid":false,"given":"Sebastien J.","family":"Hotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan L.","family":"Bramson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory R.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8675-4422","authenticated-orcid":false,"given":"Theodoros","family":"Tsakiridis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2026.218535_bib1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1590\/s1677-5538.ibju.2016.0656","article-title":"Biochemical recurrence after radical prostatectomy: what does it mean?","volume":"44","author":"Tourinho-Barbosa","year":"2018","journal-title":"Int. Braz. J. Urol."},{"key":"10.1016\/j.canlet.2026.218535_bib2","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1038\/s41467-019-11594-y","article-title":"Hsp70 and Hsp40 inhibit an inter-domain interaction necessary for transcriptional activity in the androgen receptor","volume":"10","author":"Eftekharzadeh","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218535_bib3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1158\/1535-7163.MCT-18-0432","article-title":"Hsp70 binds to the androgen receptor N-terminal domain and modulates the receptor function in prostate cancer cells","volume":"18","author":"Dong","year":"2019","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.canlet.2026.218535_bib4","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/cpt.256","article-title":"Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance","volume":"98","author":"Crona","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.canlet.2026.218535_bib5","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202152764","article-title":"The androgen receptor depends on ligand-binding domain dimerization for transcriptional activation","volume":"22","author":"El Kharraz","year":"2021","journal-title":"EMBO Rep."},{"key":"10.1016\/j.canlet.2026.218535_bib6","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/CU9.0000000000000300","article-title":"The interconnection between androgen receptor and DNA damage response pathways in prostate cancer","volume":"19","author":"Sands","year":"2025","journal-title":"Curr. Urol."},{"key":"10.1016\/j.canlet.2026.218535_bib7","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/CCO.0b013e32832a1868","article-title":"Emerging therapies in castrate-resistant prostate cancer","volume":"21","author":"Lassi","year":"2009","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.canlet.2026.218535_bib8","unstructured":"A.D. Raval, O. Lunacsek, M.J. Korn, N. Littleton, N. Constantinovici, D.J. George, Real-world evidence of combination therapy use in metastatic hormone-sensitive prostate cancer in the United States from 2017 to 2023, JCO Oncol. Pract., 0 OP-24-00690.."},{"key":"10.1016\/j.canlet.2026.218535_bib9","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218535_bib10","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in nonmetastatic, castration-resistant prostate cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218535_bib11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218535_bib12","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218535_bib13","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.juro.2012.01.080","article-title":"The influence of testosterone suppression and recovery on sexual function in men with prostate cancer: observations from a prospective study in men undergoing intermittent androgen suppression","volume":"187","author":"Ng","year":"2012","journal-title":"J. Urol."},{"key":"10.1016\/j.canlet.2026.218535_bib14","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","article-title":"Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer","volume":"378","author":"Hussain","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218535_bib15","first-page":"14","article-title":"The crucial role of AR-V7 in enzalutamide-resistance of castration-resistant prostate cancer","author":"Zheng","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218535_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14388","article-title":"Structure of the homodimeric androgen receptor ligand-binding domain","volume":"8","author":"Nadal","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218535_bib17","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.euf.2017.01.004","article-title":"Prognostic value of androgen receptor splice variant 7 in the treatment of castration-resistant prostate cancer with next generation androgen receptor signal inhibition: a systematic review and meta-analysis","volume":"4","author":"Li","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.canlet.2026.218535_bib18","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218535_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16030663","article-title":"Insight into recent advances in degrading androgen receptor for castration-resistant prostate cancer","volume":"16","author":"Chen","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218535_bib20","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1146\/annurev-pharmtox-030624-110238","article-title":"PROTACs as therapeutic modalities for drug discovery in castration-resistant prostate cancer","volume":"65","author":"Wang","year":"2025","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.canlet.2026.218535_bib21","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.molmet.2016.08.014","article-title":"The diabetes medication canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration","volume":"5","author":"Villani","year":"2016","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.canlet.2026.218535_bib22","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/s42003-023-05289-w","article-title":"The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy","volume":"6","author":"Ali","year":"2023","journal-title":"Commun. Biol."},{"key":"10.1016\/j.canlet.2026.218535_bib23","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.molmet.2016.08.014","article-title":"The diabetes medication canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration","volume":"5","author":"Villani","year":"2016","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.canlet.2026.218535_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175993","article-title":"Canagliflozin alleviates experimentally induced benign prostate hyperplasia in a rat model: exploring potential mechanisms involving mir-128b\/EGFR\/EGF and JAK2\/STAT3 signaling pathways through in silico and in vivo investigations","volume":"957","author":"Elbaz","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.canlet.2026.218535_bib25","unstructured":"(!!!INVALID CITATION !!! [22])."},{"key":"10.1016\/j.canlet.2026.218535_bib26","article-title":"(18)F-DCFPyL (PSMA) PET as a radiotherapy response assessment tool in metastatic prostate cancer","volume":"39","author":"Mesci","year":"2023","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"10.1016\/j.canlet.2026.218535_bib27","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1002\/1878-0261.13508","article-title":"Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non-small cell lung cancer (NSCLC) through inhibition of HIF-1\u03b1","volume":"17","author":"Biziotis","year":"2023","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.canlet.2026.218535_bib28","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1038\/nprot.2014.138","article-title":"The cellular thermal shift assay for evaluating drug target interactions in cells","volume":"9","author":"Jafari","year":"2014","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.canlet.2026.218535_bib29","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41598-017-18650-x","article-title":"Determining direct binders of the androgen receptor using a high-throughput cellular thermal shift assay","volume":"8","author":"Shaw","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2026.218535_bib30","doi-asserted-by":"crossref","first-page":"W159","DOI":"10.1093\/nar\/gkac394","article-title":"CB-Dock2: improved protein-ligand blind docking by integrating cavity detection, docking and homologous template fitting","volume":"50","author":"Liu","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.canlet.2026.218535_bib31","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbac087","article-title":"FitDock: protein-ligand docking by template fitting","volume":"23","author":"Yang","year":"2022","journal-title":"Briefings Bioinf."},{"key":"10.1016\/j.canlet.2026.218535_bib32","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1755-8794-3-8","article-title":"Molecular sampling of prostate cancer: a dilemma for predicting disease progression","volume":"3","author":"Sboner","year":"2010","journal-title":"BMC Med. Genom."},{"key":"10.1016\/j.canlet.2026.218535_bib33","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.1158\/0008-5472.CAN-16-0902","article-title":"Integrated classification of prostate cancer reveals a novel luminal subtype with poor outcome","volume":"76","author":"You","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218535_bib34","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1124\/mol.62.5.1027","article-title":"The mutant androgen receptor T877A mediates the proliferative but not the cytotoxic dose-dependent effects of genistein and quercetin on human LNCaP prostate cancer cells","volume":"62","author":"Maggiolini","year":"2002","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.canlet.2026.218535_bib35","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/j.febslet.2006.03.041","article-title":"DU-145 and PC-3 human prostate cancer cell lines express androgen receptor: implications for the androgen receptor functions and regulation","volume":"580","author":"Alimirah","year":"2006","journal-title":"FEBS (Fed. Eur. Biochem. Soc.) Lett."},{"key":"10.1016\/j.canlet.2026.218535_bib36","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1089\/dia.2019.0372","article-title":"Canagliflozin increases calorie intake in type 2 diabetes without changing the energy ratio of the three macronutrients: CANA-K study","volume":"22","author":"Matsuba","year":"2020","journal-title":"Diabetes Technol. Therapeut."},{"key":"10.1016\/j.canlet.2026.218535_bib37","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1593\/neo.05679","article-title":"Inhibition of decay-accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo","volume":"8","author":"Loberg","year":"2006","journal-title":"Neoplasia"},{"key":"10.1016\/j.canlet.2026.218535_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semcancer.2023.03.007","article-title":"FOXM1: a small fox that makes more tracks for cancer progression and metastasis","volume":"92","author":"Khan","year":"2023","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.canlet.2026.218535_bib39","article-title":"Oncogenic role of FOXM1 in human prostate cancer (Review)","volume":"51","author":"Lee","year":"2024","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.canlet.2026.218535_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-025-08321-5","article-title":"FOXM1 induces therapy resistance and inhibits apoptosis in a variety of human cancers","volume":"17","author":"Raghuwanshi","year":"2026","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2026.218535_bib41","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1101\/gad.13.8.966","article-title":"Roles for Nkx3.1 in prostate development and cancer","volume":"13","author":"Bhatia-Gaur","year":"1999","journal-title":"Genes Dev."},{"key":"10.1016\/j.canlet.2026.218535_bib42","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1006\/geno.1997.4715","article-title":"A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer","volume":"43","author":"He","year":"1997","journal-title":"Genomics"},{"key":"10.1016\/j.canlet.2026.218535_bib43","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0006-291X(89)92409-1","article-title":"Characterization of the prostate-specific antigen gene: a novel human kallikrein-like gene","volume":"159","author":"Riegman","year":"1989","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.canlet.2026.218535_bib44","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1006\/scbi.1997.0050","article-title":"Androgen-regulated gene expression in prostate cancer","volume":"8","author":"Trapman","year":"1997","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.canlet.2026.218535_bib45","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.biocel.2014.06.013","article-title":"Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells","volume":"54","author":"Krause","year":"2014","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.canlet.2026.218535_bib46","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1158\/0008-5472.CAN-11-3892","article-title":"Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer","volume":"72","author":"Hu","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218535_bib47","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccell.2019.01.008","article-title":"ARv7 represses tumor-suppressor genes in castration-resistant prostate cancer","volume":"35","author":"Cato","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218535_bib48","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1210\/me.2012-1016","article-title":"Direct cooperation between androgen receptor and E2F1 reveals a common regulation mechanism for androgen-responsive genes in prostate cells","volume":"26","author":"Altintas","year":"2012","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.canlet.2026.218535_bib49","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1158\/2159-8290.CD-13-0172","article-title":"Androgen receptor signaling regulates DNA repair in prostate cancers","volume":"3","author":"Polkinghorn","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218535_bib50","article-title":"MDM2 regulates the stability of AR, AR-V7, and TM4SF3 proteins in prostate cancer","volume":"4","author":"Khatiwada","year":"2024","journal-title":"Endocr. Oncol."},{"key":"10.1016\/j.canlet.2026.218535_bib51","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.omtn.2022.03.008","article-title":"m(6)A-induced repression of SIAH1 facilitates alternative splicing of androgen receptor variant 7 by regulating CPSF1","volume":"28","author":"Xia","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.canlet.2026.218535_bib52","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1111\/cas.13318","article-title":"Heat shock protein 70 inhibitors suppress androgen receptor expression in LNCaP95 prostate cancer cells","volume":"108","author":"Kita","year":"2017","journal-title":"Cancer Sci."},{"key":"10.1016\/j.canlet.2026.218535_bib53","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","article-title":"Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial","volume":"382","author":"Cefalu","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2026.218535_bib54","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s40262-015-0285-z","article-title":"Clinical pharmacokinetic, pharmacodynamic, and drug-drug interaction profile of canagliflozin, a sodium-glucose Co-transporter 2 inhibitor","volume":"54","author":"Devineni","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.canlet.2026.218535_bib55","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.clinthera.2015.04.015","article-title":"Pharmacokinetics, pharmacodynamics, and safety of single-dose canagliflozin in healthy Chinese subjects","volume":"37","author":"Chen","year":"2015","journal-title":"Clin. Ther."},{"key":"10.1016\/j.canlet.2026.218535_bib56","doi-asserted-by":"crossref","DOI":"10.1080\/10717544.2023.2241665","article-title":"Development of canagliflozin nanocrystals sublingual tablets in the presence of sodium caprate permeability enhancer: formulation optimization, characterization, in-vitro, in silico, and in-vivo study","volume":"30","author":"Fathy Elhabal","year":"2023","journal-title":"Drug Deliv."},{"key":"10.1016\/j.canlet.2026.218535_bib57","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s13318-019-00577-5","article-title":"Drug-drug interaction potential of darolutamide: in vitro and clinical studies","volume":"44","author":"Zurth","year":"2019","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.canlet.2026.218535_bib58","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/cpdd.1001","article-title":"Pharmacokinetics and use-testing of apalutamide prepared in aqueous food vehicles for alternative administration","volume":"10","author":"Yu","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.canlet.2026.218535_bib59","doi-asserted-by":"crossref","first-page":"e383","DOI":"10.1016\/j.clgc.2018.12.004","article-title":"Plasma levels of enzalutamide and its main metabolites in a patient with metastatic castration-resistant prostate cancer undergoing hemodialysis","volume":"17","author":"van Nuland","year":"2019","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.canlet.2026.218535_bib60","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140019","article-title":"Canagliflozin extends life span in genetically heterogeneous male but not female mice","volume":"5","author":"Miller","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.canlet.2026.218535_bib61","doi-asserted-by":"crossref","DOI":"10.1172\/JCI154754","article-title":"Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling","volume":"133","author":"Ding","year":"2023","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2026.218535_bib62","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/s41419-019-1646-6","article-title":"Canagliflozin inhibits growth of hepatocellular carcinoma via blocking glucose-influx-induced \u03b2-catenin activation","volume":"10","author":"Hung","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2026.218535_bib63","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.ajpath.2012.10.029","article-title":"New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells","volume":"182","author":"Lai","year":"2013","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.canlet.2026.218535_bib64","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.1128\/MCB.00159-12","article-title":"The stress response mediator ATF3 represses androgen signaling by binding the androgen receptor","volume":"32","author":"Wang","year":"2012","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2026.218535_bib65","article-title":"Associations of SGLT2i with cardiorenal outcomes among diabetics with prostate cancer on hormone therapy","author":"Koutroumpakis","year":"2024","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.canlet.2026.218535_bib66","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2025.5869","article-title":"Sodium-glucose cotransporter 2 inhibitors for patients with prostate cancer undergoing hormone therapy","author":"Shi","year":"2026","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.canlet.2026.218535_bib67","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/pros.24841","article-title":"Association of SGLT2 inhibitor initiation and PSA response in prostate cancer","volume":"85","author":"Aber","year":"2025","journal-title":"Prostate"},{"key":"10.1016\/j.canlet.2026.218535_bib68","article-title":"The effect of SGLT2 inhibition on prostate cancer: mendelian randomization and observational analysis using electronic healthcare and cohort data","volume":"5","author":"Zheng","year":"2024","journal-title":"Cell Rep. Med."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526002983?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526002983?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:00:23Z","timestamp":1792515623000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526002983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":68,"alternative-id":["S0304383526002983"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218535","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Canagliflozin is a novel androgen receptor pathway inhibitor for castrate-sensitive and castrate-resistant prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218535","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"218535"}}